Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
This article was originally published in The Tan Sheet
Executive Summary
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
You may also be interested in...
Merck Singulair Switch NDA Limits Indication To Allergies, Omits Asthma
Merck will try to convince an FDA advisory committee May 2 to partially switch its blockbuster Rx drug Singulair to OTC for allergy relief in adults only. The firm will not seek to switch the Rx indications for asthma or allergy relief in children.
Merck Singulair Switch NDA Limits Indication To Allergies, Omits Asthma
Merck will try to convince an FDA advisory committee May 2 to partially switch its blockbuster Rx drug Singulair to OTC for allergy relief in adults only. The firm will not seek to switch the Rx indications for asthma or allergy relief in children.
Merck Singulair Switch NDA Limits Indication to Allergies, Omits Asthma
Merck will try to convince an FDA advisory committee May 2 to partially switch its blockbuster Rx drug Singulair to OTC for allergy relief in adults only. The firm will not seek to switch the Rx indications for asthma or allergy relief in children.